Xeris Biopharma is executing a sharp revenue acceleration, with 28.7% YoY growth in 2026Q2 and gross margins expanding to 86.4%, signaling strong commercial traction and pricing power. Operating leverage is emerging as operating income turned positive at $5.2M...
Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.18-1582.7% vs $0.01 | $91M+1.0% vs $90M |
Q2 2026 May 7, 2026 | $0.01+465.0% vs -$0.00 | $82M+3.3% vs $80M |
Q2 2026 Mar 2, 2026 | $0.06+100.0% vs $0.03 | $86M+4.4% vs $82M |
Q4 2025 Nov 6, 2025 | $0.00-65.0% vs $0.01 | $74M-13.5% vs $86M |
Shares of Xeris Biopharma Holdings, Inc. (NASDAQ: XERS - Get Free Report) have received an average rating of "Hold" from the seven ratings firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have issued a buy
Xeris Biopharma Holdings, Inc. (XERS) Discusses XP-8121 Program Overview, Phase 3 Study Details and Commercial Strategy Transcript
Connor Clark and Lunn Investment Management Ltd. bought a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 127,107 shares of the company's stock, valued at approximately $1,007,000. Connor
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS - Get Free Report) has received an average recommendation of "Hold" from the six brokerages that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company.
Benchmark XERS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Xeris Biopharma Holdings, Inc. (XERS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $9.25 | $1.6B | 2890.63 | 43.72% | 0.19% | 4.05% | — | |
| $99.65 | $6.49B | 29.22 | 0.5% | 17.69% | 23.27% | — | |
| $42.18 | $2.45B | -62.03 | 8.63% | -13.23% | -10.42% | — | |
| $35.87 | $1.45B | 30.14 | 27.37% | 6.57% | 28.67% | — | |
| $114.03 | $12.24B | 139.05 | 12.79% | 6.61% | 8.37% | — | |
| $20.07 | $6.41B | 91.23 | 8.05% | 5.05% | — | — |
Xeris Biopharma Holdings, Inc. (XERS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Xeris Biopharma Holdings, Inc. (XERS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jul 17, 2026·SEC
Jun 30, 2026·SEC
Get notified when XERS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Xeris Biopharma Holdings, Inc. (XERS) stock FAQ — growth, dividends, profitability & financials explained
Xeris Biopharma Holdings, Inc. (XERS) reported $335.4M in revenue for fiscal year 2025. This represents a 31101% increase from $1.1M in 2016.
Xeris Biopharma Holdings, Inc. (XERS) grew revenue by 43.7% over the past year. This is strong growth.
Xeris Biopharma Holdings, Inc. (XERS) reported a net loss of $17.2M for fiscal year 2025.
Xeris Biopharma Holdings, Inc. (XERS) has a return on equity (ROE) of 4.0%. This is below average, suggesting room for improvement.
Xeris Biopharma Holdings, Inc. (XERS) generated $64.9M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
